Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1056/NEJMc1701600 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Excellent capability for molecular detection of -borne dengue, Zika, and chikungunya viruses but with a need for increased capacity for yellow fever and Japanese encephalitis viruses: an external quality assessment in 36 European laboratories.
J Clin Microbiol
December 2024
Unite des Virus Emergents (UVE: Aix-Marseille Univ, Universita di Corsica, IRD 190, Inserm 1207, IRBA), Marseille, France.
Mosquito-borne viruses represent a large global health burden. With geographic expansion of competent vectors for chikungunya virus (CHIKV), dengue virus (DENV), and Zika virus (ZIKV) in Europe, it is anticipated that the number of autochthonous cases of these tropical viruses in Europe will increase. Therefore, regular assessment of diagnostic capabilities in Europe is important.
View Article and Find Full Text PDFCTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.
Nature
November 2024
Department of Thoracic and Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Article Synopsis
- Dual immune checkpoint blockade (ICB) using CTLA4 and PD-(L)1 inhibitors shows improved anti-tumor effectiveness and immune toxicity compared to PD-(L)1 inhibitors alone in advanced non-small-cell lung cancer (NSCLC) patients.
- Patients with mutations in STK11 and/or KEAP1 genes benefit more from the combination treatment compared to those receiving only PD-(L)1 inhibitors, as shown in the POSEIDON trial.
- The loss of KEAP1 serves as a strong predictor for the success of dual ICB, as it leads to a more favorable outcome by changing the tumor's immune environment to better engage CD4 and CD8 T cells for anti-tumor activity. *
CD4 T cells with convergent TCR recombination reprogram stroma and halt tumor progression in adoptive therapy.
Sci Immunol
September 2024
David and Etta Jonas Center for Cellular Therapy, University of Chicago, Chicago, IL, USA.
Article Synopsis
- Cancer-specific T cells often fail to eliminate tumors, so researchers explored using CD4 T cell receptors (CD4TCRs) from tumor-bearers for new treatments.
- They focused on TCRs that target unique neoantigens presented by the surrounding tissue of MHC class II-negative cancer cells, testing the 11 most common TCRs.
- Some TCRs shared similar structures despite different sequences, effectively attacking tumors and reversing tumor progression; choosing TCRs based on their genetic similarities may enhance therapeutic success.
Autochthonous Cryptococcus gattii genotype VGIIb infection in a Japanese patient with anti-granulocyte-macrophage colony-stimulating factor antibodies.
J Infect Chemother
October 2024
Department of Neurology, Kanazawa Medical University, Ishikawa, Japan. Electronic address:
A 31-year-old Japanese man presented with cerebral and pulmonary cryptococcosis. Cryptococcus gattii (C. gattii) genotype VGIIb was detected in the patient's sputum and cerebrospinal fluid specimens.
View Article and Find Full Text PDFOne CD4+TCR and One CD8+TCR Targeting Autochthonous Neoantigens Are Essential and Sufficient for Tumor Eradication.
Clin Cancer Res
April 2024
David and Etta Jonas Center for Cellular Therapy, The University of Chicago, Chicago, Illinois.
Purpose: To achieve eradication of solid tumors, we examined how many neoantigens need to be targeted with how many T-cell receptors (TCR) by which type of T cells.
Experimental Design: Unmanipulated, naturally expressed (autochthonous) neoantigens were targeted with adoptively transferred TCR-engineered autologous T cells (TCR-therapy). TCR-therapy used CD8+ T-cell subsets engineered with TCRs isolated from CD8+ T cells (CD8+TCR-therapy), CD4+ T-cell subsets engineered with TCRs isolated from CD4+ T cells (CD4+TCR-therapy), or combinations of both.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!